Skip to main content
. 2017 Apr 10;8(20):33807–33826. doi: 10.18632/oncotarget.16995

Figure 3. U0126 inhibits ERK1/2 activation in the kidney of hyperuricemic rats.

Figure 3

(A) ERK1/2 was activated in the kidney of HN rats in a time-dependent manner. The kidneys were taken for immunoblot analysis of p-ERK1/2, ERK1/2 or glyceraldehyde 3-phosphate dehydrogenase (GAPDH); the representative results are shown. (B and D) Expression level of p-ERK1/2 was quantified by densitometry and normalized with total ERK1/2. (C) Rat model of HN was established by feeding with adenine and potassium oxonate daily. In some rats, U0126 were simultaneously administrated intraperitoneally. After 28 days, the kidneys were taken for immunoblot analysis of p-ERK1/2, ERK1/2 or GAPDH. Data are represented as the mean±SEM (n=6). Means with different letters are significantly different from one another (P<0.05).